Patents by Inventor Karl Clauser
Karl Clauser has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20260097115Abstract: Immunogenic compositions comprising one or more peptides, wherein the one or more peptides: are capable of binding to Major Histocompatibility Complex (MHC) class II, and are derived from one or more translation products of SARS-CoV-2. Also provided include methods of treating and preventing diseases using the immunogenic compositions.Type: ApplicationFiled: December 9, 2025Publication date: April 9, 2026Inventors: Shira Weingarten-Gabbay, Da-Yuan Chen, Siranush Sarkizova, Karl Clauser, Nir Hacohen, Steven Carr, Jennifer Abelin, Mohsan Saeed, Pardis Sabeti
-
Patent number: 12419948Abstract: Immunogenic compositions comprising one or more polypeptides, wherein the one or more polypeptides: is capable of binding to Major Histocompatibility Complex (MHC) class I, and is derived from one or more proteins of SARS-COV-2. Also provided include methods of treating and preventing diseases using the immunogenic compositions.Type: GrantFiled: August 31, 2021Date of Patent: September 23, 2025Assignees: The Broad Institute, Inc., President and Fellows of Harvard College, The General Hospital Corporation, Trustees of Boston UniversityInventors: Pardis Sabeti, Shira Weingarten-Gabbay, Susan Klaeger, Jenn Abelin, Mohsan Saeed, Nir Hacohen, Siranush Sarkizova, Steven Carr, Karl Clauser
-
Publication number: 20220088180Abstract: Immunogenic compositions comprising one or more polypeptides, wherein the one or more polypeptides: is capable of binding to Major Histocompatibility Complex (MHC) class I, and is derived from one or more proteins of SARS-CoV-2. Also provided include methods of treating and preventing diseases using the immunogenic compositions.Type: ApplicationFiled: August 31, 2021Publication date: March 24, 2022Inventors: Pardis SABETI, Shira Weingarten-Gabbay, Susan Klaeger, Jenn Abelin, Mohsan Saeed, Nir Hacohen, Siranush Sarkizova, Steven Carr, Karl Clauser
-
Publication number: 20220062394Abstract: Disclosed herein are polypeptides and compositions comprising one or more neoantigens, methods of identifying neoantigens, and methods for preparing a neoantigen for an immunogenic pharmaceutical composition. The neoantigen can be specific to a subject that has a cancer, disease, or other disorder.Type: ApplicationFiled: December 12, 2019Publication date: March 3, 2022Inventors: Tamara Ouspenskaia, Travis Law, Aviv Regev, Steven Carr, Karl Clauser, Susan Klaeger, Nir Haochen, Catherine J. Wu, Derin Keskin
-
Publication number: 20210382068Abstract: Adaptive immune responses rely on the ability of cytotoxic T cells to identify and eliminate cells displaying disease-specific antigens on human leukocyte antigen (HLA) class I molecules. Investigations into antigen processing and display have immense implications in human health, disease and therapy. To extend understanding of the rules governing antigen processing and presentation, immunopurified peptides from B cells, each expressing a single HLA class I allele, were profiled. A resource dataset containing thousands of peptides bound to distinct class I HLA-A, -B, and -C alleles was generated by implementing a novel allele-specific database search strategy. Applicants discovered new binding motifs, established the role of gene expression in peptide presentation and improved prediction of HLA-peptide binding by using these data to train machine-learning models. These streamlined experimental and analytic workflows enable direct identification and analysis of endogenously processed and presented antigens.Type: ApplicationFiled: October 2, 2019Publication date: December 9, 2021Inventors: Derin Keskin, Siranush Sarkizova, Susan Klaeger, Karl Clauser, Steven Carr, Nir Hacohen, Catherine J. Wu
-
Patent number: 10024860Abstract: Proteomic methods for identifying cancer related proteins and related products and kits are provided. The cancer specific proteins are extracellular matrix proteins that are associated with various aspects of cancer. Panels or signature sets of proteins useful in the detection, diagnosis and treatment of cancers as well as monitoring therapeutic progress in a cancer patient are provided herein along with methods for their detection and for their use in targeting imaging and/or therapeutic agents to the tumors via binding to the specified proteins. The proteins were identified using proteomics analyzes of tissue samples taken from cancer patients. In certain aspects the proteins are particularly useful in colon cancer patients.Type: GrantFiled: September 22, 2016Date of Patent: July 17, 2018Assignees: Massachusetts Institute of Technology, The General Hospital Corporation, The Broad Institute, Inc.Inventors: Richard O. Hynes, Alexandra Naba, Karl Clauser, Steven A. Carr, Kenneth Tanabe
-
Publication number: 20170343553Abstract: Proteomic methods for identifying cancer related proteins and related products and kits are provided. The cancer specific proteins are extracellular matrix proteins that are associated with various aspects of cancer. Panels or signature sets of proteins useful in the detection, diagnosis and treatment of cancers as well as monitoring therapeutic progress in a cancer patient are provided herein along with methods for their detection and for their use in targeting imaging and/or therapeutic agents to the tumors via binding to the specified proteins. The proteins were identified using proteomics analyses of tissue samples taken from cancer patients. In certain aspects the proteins are particularly useful in colon cancer patients.Type: ApplicationFiled: September 22, 2016Publication date: November 30, 2017Applicants: Massachusetts Institute of Technology, The General Hospital Corporation d/b/a Massachusettes General Hospital, The Broad Institute, Inc.Inventors: Richard O. Hynes, Alexandra Naba, Karl Clauser, Steven A. Carr, Kenneth Tanabe
-
Publication number: 20170051073Abstract: Proteomic methods for identifying cancer related proteins and related products and kits are provided. The cancer specific proteins are extracellular matrix proteins that are associated with various aspects of cancer. Panels or signature sets of proteins useful in the detection, diagnosis and treatment of cancers as well as monitoring therapeutic progress in a cancer patient are provided herein along with methods for their detection and for their use in targeting imaging and/or therapeutic agents to the tumors via binding to the specified proteins. The proteins were identified using proteomics analyses of tissue samples taken from cancer patients. In certain aspects the proteins are particularly useful in colon cancer patients.Type: ApplicationFiled: September 22, 2016Publication date: February 23, 2017Applicants: Massachusetts Institute of Technology, The General Hospital Corporation d/b/a Massachusettes General Hospital, The Broad Institute, Inc.Inventors: Richard O. Hynes, Alexandra Naba, Karl Clauser, Steven A. Carr, Kenneth Tanabe
-
Patent number: 9526800Abstract: Proteomic methods for identifying cancer related proteins and related products and kits are provided. The cancer specific proteins are extracellular matrix proteins that are associated with various aspects of cancer. Panels or signature sets of proteins useful in the detection, diagnosis and treatment of cancers as well as monitoring therapeutic progress in a cancer patient are provided herein along with methods for their detection and for their use in targeting imaging and/or therapeutic agents to the tumors via binding to the specified proteins. The proteins were identified using proteomics analyzes of tissue samples taken from cancer patients. In certain aspects the proteins are particularly useful in colon cancer patients.Type: GrantFiled: March 14, 2013Date of Patent: December 27, 2016Assignees: Massachusetts Institute of Technology, The General Hospital Corporation, The Broad Institute, Inc.Inventors: Richard O. Hynes, Alexandra Naba, Karl Clauser, Steven A. Carr, Kenneth Tanabe
-
Publication number: 20150086565Abstract: Proteomic methods for identifying cancer related proteins and related products and kits are provided. The cancer specific proteins are extracellular matrix proteins that are associated with various aspects of cancer. Panels or signature sets of proteins useful in the detection, diagnosis and treatment of cancers as well as monitoring therapeutic progress in a cancer patient are provided herein along with methods for their detection and for their use in targeting imaging and/or therapeutic agents to the tumors via binding to the specified proteins. The proteins were identified using proteomics analyses of tissue samples taken from cancer patients. In certain aspects the proteins are particularly useful in colon cancer patients.Type: ApplicationFiled: March 14, 2013Publication date: March 26, 2015Applicants: Massachusetts Institute of Technology, The General Hospital Corporaiton d/b/a Massachusetts General Hospital, The Broad Institute, Inc.Inventors: Richard O. Hynes, Alexandra Naba, Karl Clauser, Steven A. Carr, Kenneth Tanabe